Skip to content
Screener

Cogent Biosciences, Inc. COGT Other income, net (Note 6)

Other income, net (Note 6) at other companies

Pfizer logo
PfizerPFE
$3.72B+603%
Incyte logo
IncyteINCY
$6.28M-14.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$1.08M+0.5%
Relay Therapeutics, Inc. logo
Relay Therapeutics, Inc.RLAY
$7.12M+10.0%
CytomX Therapeutics logo
CytomX TherapeuticsCTMX
$18K+5.9%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
-$98K+45.9%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$7.14B+366%
Enterprise value$6.92B+372%

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.

The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 8:21 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-205170
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Other income:
Interest income7,6082,952
Interest expense(1,213)
Other income (expense), net(140)(5)
Total other income, net6,2552,947
Net loss$(97,352)$(71,986)
Net loss per share, basic and diluted, Series A non-voting convertible preferred stock$(132.58)$(131.22)
Weighted average Series A non-voting convertible preferred stock outstanding, basic and diluted67,41467,892

Item 1. Financial Statements (Unaudited)

FAQ

What is Cogent Biosciences, Inc.'s other income, net (note 6)?
Cogent Biosciences, Inc. (COGT) reported other income, net (note 6) of -$140K in Q1 2026.
How has Cogent Biosciences, Inc.'s other income, net (note 6) changed year-over-year?
Cogent Biosciences, Inc.'s other income, net (note 6) decreased by 2700.0% year-over-year, from -$5K to -$140K.
What is the long-term trend for Cogent Biosciences, Inc.'s other income, net (note 6)?
Over 2 years (2023 to 2025), Cogent Biosciences, Inc.'s other income, net (note 6) has grown at a -85.5% compound annual growth rate (CAGR), from $950K to -$20K.
What does other income, net (note 6) mean?
This captures miscellaneous financial items that fall outside the scope of core operating activities, such as foreign exchange gains or losses, minor investment income, or non-recurring legal settlements. It serves as a catch-all for peripheral financial events that do not stem from the primary business operations. Investors monitor this to isolate core earnings from transient or incidental financial fluctuations.

Ask your AI about Cogent Biosciences, Inc.'s other income, net (note 6).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude